Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Operating Expenses (2018 - 2025)

Lineage Cell Therapeutics' Other Operating Expenses history spans 9 years, with the latest figure at $66000.0 for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 57.14% year-over-year to $66000.0; the TTM value through Dec 2025 reached $15.0 million, up 4386.83%, while the annual FY2025 figure was $15.0 million, 4386.83% up from the prior year.
  • Other Operating Expenses reached $66000.0 in Q4 2025 per LCTX's latest filing, up from $5000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $14.9 million in Q2 2025 to a low of $5000.0 in Q3 2025.
  • Average Other Operating Expenses over 3 years is $1.4 million, with a median of $98000.0 recorded in 2024.
  • The largest YoY upside for Other Operating Expenses was 33715.91% in 2025 against a maximum downside of 86.84% in 2025.
  • A 3-year view of Other Operating Expenses shows it stood at $169000.0 in 2023, then dropped by 8.88% to $154000.0 in 2024, then plummeted by 57.14% to $66000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Other Operating Expenses are $66000.0 (Q4 2025), $5000.0 (Q3 2025), and $14.9 million (Q2 2025).